Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer.
Minority vote to statement A5 of the Fourth Ovarian Cancer Consensus Conference, Vancouver 2010, on behalf of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Germany plus North-Eastern Society of Gyneco-Oncology and the AGO Austria.